An observational study in Sepsis, sponsored by Edwards Lifesciences. Status unknown at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.
Sponsored by Edwards Lifesciences · Observational
To investigate the relationship between initial ClearSight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed ICU admission) in patients with acute infection and possible sepsis, with a focus on venous blood lactate (\< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's planned enrollment of 182 is above the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →Edwards Lifesciences is the lead sponsor of 124 studies on the registry; 19 are open to participants now.
Of its 34 completed or terminated interventional studies of FDA-regulated products, 32 (94%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with acute infection and possible sepsis, with a focus on venous blood lactate (\< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).
Venous Blood Lactate Groups
Inclusion Criteria:
Exclusion Criteria:
Control Sepsis Mimic
Inclusion Criteria:
Exclusion Criteria:
Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
Device: ClearSight™ / EV1000NI Clinical Platform
Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
Device: ClearSight™ / EV1000NI Clinical Platform
Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
Device: ClearSight™ / EV1000NI Clinical Platform
Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
Device: ClearSight™ / EV1000NI Clinical Platform
Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
Composite outcome
Increase in modified Sequential Organ Failure Assessment (mSOFA) score ≥ 1 resulting in ICU admission / death.
Time frame: Within 72 hours of presentation
Venous Blood Lactate clearance
Venous Blood Lactate clearance
Time frame: Within 24 and 72 hours of presentation
Length of Stay
Emergency Department length of stay, ICU length of stay, and Hospital length of stay
Time frame: 30 days
Recidivism
Recidivism within 30 days of the index hospital visit
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Edwards Lifesciences